Utilizing alternative reading frames, the mammalian ARF-INK4a locus encodes two unrelated proteins that both function in tumor suppression, ARF and the cell cycle inhibitor, p16. ARF binds with MDM2 and blocks MDM2-directed ubiquitination of p53 and p53 nuclear export, thus preventing cytoplasmic degradation of p53. Previously, we, and others, found that human ARF binds the MDM2 oncoprotein leading to stabilization and transcriptional activation of p53 with a resultant proliferative arrest. ARF levels are increased through transcription following exposure to oncogenic stimuli, but post-translational regulation of ARF is largely unexplored. Recently, we have found a novel protein, LZAP, (leucine zipper containing ARF-binding protein) that binds ARF in the nucleus and regulates ARF biochemical activity toward MDM2. In addition to its regulation of MDM2 activity, ARF has recently been found to have p53-independent effects including S-phase growth delay, regulation of rRNA processing and inhibition of the nuclear factor kappa B (NF-kB), that may contribute to p53-independent effects of ARF observed in tumorigenesis. In addition to its regulation of ARF, we initially explored the role of LZAP in regulation of NF-kB activity and found that expression of LZAP decreased both basal and cytokine stimulated NF-kB activity, while inhibition of endogenous LZAP expression resulted in increased basal NF-kB activity. Remarkably, LZAP was found to bind directly to NFkB within cells. We have identified a novel protein that regulates ARF activity toward MDM2 and decreases NF-kB activity. Given the importance of ARF and NF-kB in tumorigenesis, the biochemical activities of LZAP suggest that it may serve as a tumor suppressor. We will further evaluate the role of LZAP in regulation of ARF and NF-kB activity and determine if LZAP has tumor suppressor activity. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE013173-06
Application #
7057778
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Shirazi, Yasaman
Project Start
2005-05-01
Project End
2010-04-30
Budget Start
2006-05-01
Budget End
2007-04-30
Support Year
6
Fiscal Year
2006
Total Cost
$373,105
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Lu, X; An, H; Jin, R et al. (2014) PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene 33:2918-27
Liu, Dan; Wang, Wen-Der; Melville, David B et al. (2011) Tumor suppressor Lzap regulates cell cycle progression, doming, and zebrafish epiboly. Dev Dyn 240:1613-25
An, Hanbing; Lu, Xinyuan; Liu, Dan et al. (2011) LZAP inhibits p38 MAPK (p38) phosphorylation and activity by facilitating p38 association with the wild-type p53 induced phosphatase 1 (WIP1). PLoS One 6:e16427
Wang, Jialiang; An, Hanbing; Mayo, Marty W et al. (2007) LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 12:239-51
Wang, Jialiang; He, Xiaping; Luo, Ying et al. (2006) A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. Biochem J 393:489-501
Yarbrough, Wendell G; Bessho, Mika; Zanation, Adam et al. (2002) Human tumor suppressor ARF impedes S-phase progression independent of p53. Cancer Res 62:1171-7
Yarbrough, Wendell G (2002) The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope 112:2114-28
Hutchin, M E; Pickles, R J; Yarbrough, W G (2000) Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum Gene Ther 11:2365-75